HYP - ETF AI Analysis
Top Page
Golden Eagle Dynamic Hypergrowth ETF (HYP)
HYP (Golden Eagle Dynamic Hypergrowth ETF) has a mid-range overall rating, reflecting a mix of promising growth stories and meaningful risks. Strong holdings like CareDx, Hinge Health, and Materion support the fund’s quality through solid revenue growth, improving profitability, and strategic positions in attractive markets, while weaker names such as Kosmos Energy, ImmunityBio, and Oscar Health face financial and technical challenges that drag on the fund’s appeal. The main risk factor is the ETF’s focus on hypergrowth companies with ongoing profitability and valuation concerns, which can lead to higher volatility and uncertainty for investors.
HYP vs. SPDR S&P 500 ETF (SPY)
- AUM
- 33.24M
- Region
- North America
- Expense Ratio
- 0.85%
- Beta
- 1.76
- Issuer
- Golden Eagle
- Inception Date
- Sep 23, 2025
- Dividend Yield
- 0.14%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
HYP Summary
The Golden Eagle Dynamic Hypergrowth ETF (HYP) is an actively managed fund that hunts for fast-growing U.S. companies, rather than tracking a fixed index. It focuses on businesses with very strong sales growth across the whole market, with a big tilt toward technology, energy, and health care. Well-known names like Dell Technologies and Avnet appear among its top holdings. Someone might invest in HYP if they want exposure to companies that could grow quickly and are comfortable with an aggressive, growth-focused approach. A key risk is that these hypergrowth stocks can be very volatile, so the ETF’s value can rise and fall sharply with market swings.
How much will it cost me?
This ETF has an expense ratio of 0.85%, which means you’ll pay about $8.50 per year for every $1,000 you invest. That’s higher than the average ETF because it’s actively managed, using a specialized strategy to pick and adjust high-growth stocks rather than simply tracking a broad market index.
What would affect this ETF?
HYP could benefit if the U.S. economy stays strong, innovation in technology and health care accelerates, and energy prices support growth for its energy holdings, helping high-growth companies like Hinge Health and CareDx expand. On the other hand, rising interest rates, market downturns that hit growth stocks hardest, regulatory changes in health care or energy, or setbacks at key holdings such as Oscar Health and Kosmos Energy could hurt future performance.
HYP Top 10 Holdings
HYP is leaning hard into U.S. hypergrowth tech, with names like MaxLinear, Lumentum, and Viavi acting as the fund’s main engines as AI and cloud themes gain traction. Dell adds a steadier, rising tech heavyweight to the mix, helping smooth out some of the bumps from more volatile smaller players. On the flip side, Applied Optoelectronics and Oscar Health look more like dead weight for now, with profitability and cash flow issues holding them back. Energy names such as PBF Energy and Kosmos provide a rising but secondary boost, giving the fund a bit of cyclical balance without diluting its tech-first story.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 HNGE | Hinge Health, Inc. Class A | 2.70% | $844.39K | $9.22B | 132.07% | 70Outperform |
 CDNA | CareDx | 1.76% | $548.94K | $4.59B | 472.53% | 77Outperform |
 PENG | Penguin Solutions | 2.45% | $766.93K | $3.13B | 113.29% | 61Neutral |
 KOS | Kosmos Energy | 0.96% | $301.20K | $1.70B | 57.32% | 47Neutral |
 ETON | Eton Pharmaceuticals | 2.55% | $797.51K | $1.49B | 182.12% | 56Neutral |
 OSCR | Oscar Health | 2.68% | $838.98K | $9.38B | 72.22% | 49Neutral |
 PBF | PBF Energy | 1.07% | $333.51K | $9.25B | 119.72% | 55Neutral |
 LITE | Lumentum Holdings | 2.17% | $677.56K | $76.15B | 239.55% | 61Neutral |
 AVT | Avnet | 1.13% | $352.98K | $7.25B | 78.00% | 67Neutral |
 MTRN | Materion | 1.11% | $346.73K | $4.62B | 89.17% | 69Neutral |
HYP Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HYP, the sentiment is Negative. The current price of 23.63 is below the 20-day moving average (MA) of 27.17, below the 50-day MA of 27.33, and below the 200-day MA of 27.43, indicating a bearish trend. The MACD of -0.84 indicates Positive momentum. The RSI at 31.01 is Neutral, neither overbought nor oversold. The STOCH value of 29.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HYP.
HYP Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| HYP | $23.63 | $31.00(31.21% Upside) | $33.24M | 0.85% | 59Neutral |
 TSEL | $26.30 | $36.69(39.49% Upside) | $76.92M | 0.67% | 70Neutral |
 SEMG | $27.28 | $34.56(26.69% Upside) | $63.84M | 0.60% | 72Outperform |
 ZDIS | $54.02 | $77.08(42.68% Upside) | $60.65M | 0.75% | 64Neutral |
 JGRW | $28.78 | $34.20(18.81% Upside) | $62.28M | 0.57% | 75Outperform |
 NSIG | $23.56 | $31.39(33.24% Upside) | $58.51M | 0.38% | 74Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HYP | Golden Eagle Dynamic Hypergrowth ETF | 23.63 | -0.12 | -0.51% | |
| TSEL | Touchstone Sands Capital US Select Growth ETF | 26.30 | -3.13 | -10.64% | |
| SEMG | Suncoast Select Growth ETF | 27.27 | 0.37 | 1.37% | |
| ZDIS | Virtus Zevenbergen Discovery Growth ETF | 54.02 | -9.81 | -15.38% | |
| JGRW | Jensen Quality Growth ETF | 28.78 | 2.01 | 7.51% | |
| NSIG | North Square Growth Opportunities ETF | 23.56 | -1.75 | -6.92% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.